Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

BRCA2 mutations in primary breast and ovarian cancers

Abstract

The second hereditary breast cancer gene, BRCA2, was recently isolated1. Germline mutations of this gene predispose carriers to breast cancer, and, to a lesser extent, ovarian cancer. Loss of heterozygosity (LOH) at the BRCA2 locus has been observed in 30–40% of sporadic breast and ovarian tumours, implying thatBRCA2 may act as a tumour suppressor gene in a proportion of sporadic cases 2–5. To define the role of BRCA2 in sporadic breast and ovarian cancer, we screened the entire gene for mutations using a combination of techniques in 70 primary breast carcinomas and in 55 primary epithelial ovarian carcinomas. Our analysis revealed alterations in 2/70 breast tumours and none of the ovarian carcinomas. One alteration found in the breast cancers was a 2-basepair (bp) deletion (4710delAG) which was subsequently shown to be a germline mutation, the other was a somatic missense mutation (Asp3095Glu) of unknown significance. Our results suggest that BRCA2 is a very infrequent target for somatic inactivation in breast and ovarian carcinomas, similar to the results obtained torBRCAL

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Wooster, R. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789–792 (1995).

    Article  CAS  PubMed  Google Scholar 

  2. Lundberg, C. et al. Loss of heterozygosity in human ductal breast tumours indicates a recessive mutation on chromosome 13. Proc. Natl. Acad. Sci. USA 84, 2372–2376 (1987).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Kim, T.M. et al. Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian eptithelial tumors and is associated with normal retinoblastoma expression. Cancer Res. 54, 605–609 (1994).

    CAS  PubMed  Google Scholar 

  4. Collins, N. et al. Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene chromosome 13q12–13. Oncogene 10, 1673–1675 (1995).

    CAS  PubMed  Google Scholar 

  5. Cleton-Jansen, A.M. et al.Loss of heterozygosity in sporadic breast tumors at the BRCA2 locus on chromosome 13q12–13. Br.J.Cancer 72, 1241–1244 (1995).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Phelan, C.M. et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nature Genet. 13, 120–122 (1996).

    Article  CAS  PubMed  Google Scholar 

  7. Futreal, P.A. et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266, 120–122 (1994).

    Article  CAS  PubMed  Google Scholar 

  8. Merajver, S.A. et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genet. 9, 439–443 (1995).

    Article  CAS  PubMed  Google Scholar 

  9. Hosking, L. et al. A somatic BRCA1 mutation in an ovarian tumour. Nature Genet. 9, 343–344 (1995).

    Article  CAS  PubMed  Google Scholar 

  10. Takahashi, H. et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res. 55, 2998–3002 (1995).

    CAS  PubMed  Google Scholar 

  11. Kerangueven, F. et al. Patterns of loss of heterzygosity at loci from chromosome arm 13q suggest a possible involvement of BRCA2 in sporadic breast tumors. Genes Chrom. Cancer 13, 291–294 (1995).

    Article  CAS  PubMed  Google Scholar 

  12. Chen, Y et al.Aberrant subcellular localization of BRCA1 in breast cancer. Science 270, 789–791 (1995).

    Article  CAS  PubMed  Google Scholar 

  13. Thompson, M.E., Jensen, R.A., Obermiller, P.S., Page, D.L. & Holt, J.T. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nature Genet. 9, 444–450 (1995).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to P. Andrew Futreal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lancaster, J., Wooster, R., Mangion, J. et al. BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 13, 238–240 (1996). https://doi.org/10.1038/ng0696-238

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng0696-238

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing